Search

Supplemental Material, sj-pdf-2-prf-10.1177_02676591211057506 for The Interplay of Inflammation and Coagulation in COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation Support by Akram Zaaqoq, Tariq Sallam, Caitlin Merley, Lan Anh Galloway, Sameer Desale, Jobin Varghese, Muhtadi Alnababteh, Eric Kriner, Hiroto Kitahara, Jeffrey Shupp, Heidi Dalton and Ezequiel Molina in Perfusion

Supplemental Material, sj-pdf-2-prf-10.1177_02676591211057506 for The Interplay of Inflammation and Coagulation in COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation Support by Akram Zaaqoq, Tariq Sallam, Caitlin Merley, Lan Anh Galloway, Sameer Desale, Jobin Varghese, Muhtadi Alnababteh, Eric Kriner, Hiroto Kitahara, Jeffrey Shupp, Heidi Dalton and Ezequiel Molina in Perfusion

Supplemental Material, sj-pdf-1-prf-10.1177_02676591211057506 for The Interplay of Inflammation and Coagulation in COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation Support by Akram Zaaqoq, Tariq Sallam, Caitlin Merley, Lan Anh Galloway, Sameer Desale, Jobin Varghese, Muhtadi Alnababteh, Eric Kriner, Hiroto Kitahara, Jeffrey Shupp, Heidi Dalton and Ezequiel Molina in Perfusion

Supplemental Material, sj-pdf-1-prf-10.1177_02676591211057506 for The Interplay of Inflammation and Coagulation in COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation Support by Akram Zaaqoq, Tariq Sallam, Caitlin Merley, Lan Anh Galloway, Sameer Desale, Jobin Varghese, Muhtadi Alnababteh, Eric Kriner, Hiroto Kitahara, Jeffrey Shupp, Heidi Dalton and Ezequiel Molina in Perfusion

Background Acute respiratory distress syndrome (ARDS) is a major complication in patients with severe coronavirus disease in 2019 (COVID-19). COVID-19 convalescent plasma (CCP) has been proposed as a specific therapy for patients with COVID-19. Our goal is to assess changes in oxygenation and inflammatory markers in patients after receiving CCP. Methods This is a retrospective, health system-based, a case-control study comparing hospitalized patients with COVID-19 who received CCP and were discharged (survivors) to patients who died after receiving CCP (non-survivors). We analyzed the severity of ARDS, oxygenation, and inflammatory markers of 295 patients, comparing 202 survivors to 93 non-survivors with COVID-19 who received CCP. Demographic information and laboratory data were collected on the day of the admission (initial), the day of the plasma infusion (D1), and post-infusion days 3, 7, 15, and 30 (when available). Results Survivors were younger (52.48 y versus 64.02 y; p Conclusion In this retrospective, health system-based, case-control study, we found that the improvement in oxygenation, resolution of ARDS, and reduced inflammatory markers are seen in survivor patients after early COVID-19 convalescent plasma transfusion. These parameters can be used to assess response to COVID-19 convalescent plasma after 72 hours of the transfusion and could help physicians in the decision-making when administering CCP, especially if resources are scarce. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Supplemental material, KMPHOTOGONIOMETRY_appendix for Viability of Hand and Wrist Photogoniometry by Clifton G. Meals, Rebecca J. Saunders, Sameer Desale, and Kenneth R. Means in HAND